281 related articles for article (PubMed ID: 15907761)
41. [New drugs for the treatment of human parasitic protozoa].
Dupouy-Camet J
Parassitologia; 2004 Jun; 46(1-2):81-4. PubMed ID: 15305692
[TBL] [Abstract][Full Text] [Related]
42. Polyamine synthesis and salvage pathways in the malaria parasite Plasmodium falciparum.
Ramya TN; Surolia N; Surolia A
Biochem Biophys Res Commun; 2006 Sep; 348(2):579-84. PubMed ID: 16890916
[TBL] [Abstract][Full Text] [Related]
43. [Polyamines and cell growth: specific aspects in Amoeba proteus and in certain cancer cell lines].
Dubois J; Schenkel E; Hanocq M
Bull Mem Acad R Med Belg; 1995; 150(5-6):252-7; discussion 257-8. PubMed ID: 8696270
[TBL] [Abstract][Full Text] [Related]
44. Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa.
Turrens JF
Mol Aspects Med; 2004; 25(1-2):211-20. PubMed ID: 15051329
[TBL] [Abstract][Full Text] [Related]
45. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells.
Jun JY; Griffith JW; Bruggeman R; Washington S; Demers LM; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Jan; 107(1):33-40. PubMed ID: 17333337
[TBL] [Abstract][Full Text] [Related]
46. Genetic and biochemical analysis of protozoal polyamine transporters.
Hasne MP; Ullman B
Methods Mol Biol; 2011; 720():309-26. PubMed ID: 21318882
[TBL] [Abstract][Full Text] [Related]
47. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
48. Metabolic reconstruction and analysis for parasite genomes.
Pinney JW; Papp B; Hyland C; Wambua L; Westhead DR; McConkey GA
Trends Parasitol; 2007 Nov; 23(11):548-54. PubMed ID: 17950669
[TBL] [Abstract][Full Text] [Related]
49. [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].
Reguera RM; Pérez-Pertejo Y; Redondo CM; Díaz-González R; Balaña-Fouce R
Medicina (B Aires); 2007; 67(6 Pt 2):747-57. PubMed ID: 18422072
[TBL] [Abstract][Full Text] [Related]
50. Polyamines: metabolism and implications in human diseases.
Moinard C; Cynober L; de Bandt JP
Clin Nutr; 2005 Apr; 24(2):184-97. PubMed ID: 15784477
[TBL] [Abstract][Full Text] [Related]
51. Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa.
Grant KM
Curr Pharm Des; 2008; 14(9):917-24. PubMed ID: 18473840
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive analysis of polyamine transport and biosynthesis in the dominant human gut bacteria: Potential presence of novel polyamine metabolism and transport genes.
Sugiyama Y; Nara M; Sakanaka M; Gotoh A; Kitakata A; Okuda S; Kurihara S
Int J Biochem Cell Biol; 2017 Dec; 93():52-61. PubMed ID: 29102547
[TBL] [Abstract][Full Text] [Related]
53. Content, synthesis, and function of polyamines in trypanosomatids: relationship to chemotherapy.
Bacchi CJ
J Protozool; 1981 Feb; 28(1):20-7. PubMed ID: 6788943
[No Abstract] [Full Text] [Related]
54. Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both?
Wang Y; Casero RA
J Biochem; 2006 Jan; 139(1):17-25. PubMed ID: 16428315
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy.
Seiler N
Pharmacol Ther; 2005 Jul; 107(1):99-119. PubMed ID: 15963353
[TBL] [Abstract][Full Text] [Related]
56. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections.
Geurts N; Opdenakker G; Van den Steen PE
Pharmacol Ther; 2012 Mar; 133(3):257-79. PubMed ID: 22138604
[TBL] [Abstract][Full Text] [Related]
57. Tumour growth modifies intravascular polyamine transport by plasma lipoproteins in the mouse.
Catros-Quemener V; Leray G; Moulinoux JP; Havouis R; de Certaines JD; Chapman J
Biochim Biophys Acta; 1997 May; 1346(1):30-7. PubMed ID: 9187300
[TBL] [Abstract][Full Text] [Related]
58. Agmatine transport into spinal nerve terminals is modulated by polyamine analogs.
Goracke-Postle CJ; Overland AC; Stone LS; Fairbanks CA
J Neurochem; 2007 Jan; 100(1):132-41. PubMed ID: 17227436
[TBL] [Abstract][Full Text] [Related]
59. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
60. Polyamine analogues as anticancer drugs.
Wallace HM; Fraser AV
Biochem Soc Trans; 2003 Apr; 31(2):393-6. PubMed ID: 12653646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
